Drug utilization statistics for individual-level pharmacy dispensing data

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 7, 2005, Pages 455-463

  Hallas, Jesper ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Databases; Drug utilization; Duration; Incidence; Prescribing patterns; Prevalence

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; HYPOCHOLESTEROLEMIC AGENT; INSULIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL ANTIDIABETIC AGENT; VASODILATOR AGENT;

ADULT; ASTHMA; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; DEPRESSION; DIABETES MELLITUS; DRUG USE; DRUG UTILIZATION; EPIDEMIOLOGICAL DATA; EPILEPSY; FEMALE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; MALE; MENTAL DISEASE; OBSTRUCTIVE AIRWAY DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGE FACTORS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATA COLLECTION; DATABASES, FACTUAL; DENMARK; DRUG THERAPY; DRUG UTILIZATION; EPIDEMIOLOGIC METHODS; HUMANS; INCIDENCE; MODELS, STATISTICAL; PHARMACEUTICAL SERVICES; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; TIME FACTORS;

EID: 22244488721     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1063     Document Type: Review

References (35)

1. WHO Expert Committee. The Selection of Essential Drugs. Technical Report Series No. 615. Geneva, World Health Organization, 1977.
2. Lee D, Bergman U. Studies of drug utilization. In Pharmacoepidemiology, Strom BL (ed.), 3rd edn. Wiley and Sons: Chichester, 1999; 463.
3. World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignments. World Health Organization Collaborating Centre for Drug Statistics Methodology: Oslo, 2001.
4. Gaist D, Sørensen HT, Hallas J. The Danish prescription registers. Dan Med Bull 1997; 44: 445-448.
5. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC Classification Index with DDDs. World Health Organization Collaborating Centre for Drug Statistics Methodology: Oslo, 2003, www.whocc.no.
6. Sartor F, Walckiers D. Estimate of disease prevalence using drug consumption data. Am J Epidemiol 1995; 141: 782-787.
7. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol 2001; 54: 1181-1186.
8. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. An approach for the estimation of drug prescribing using the defined daily dose methodology and drug dispensation data: theoretical considerations and practical applications. Eur J Clin Pharmacol 2000; 56: 513-517.
9. Bjerrum L, Rosholm JU, Hallas J, Kragstrup, J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997; 53: 7-11.
10. van Staa TP, Abenhaim L, Leufkens H. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol 1994; 47: 183-189.
11. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619-625.
12. Rothman KJ, Greenland S. Measures of disease frequency. In Modern Epidemiology, Rothman KJ, Greenland (eds). Lippincott-Raven: Philadelphia, 1998; 43.
13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
14. Barnard RJ, Jung T, Inkeles SB. Diet and exercise in the treatment of NIDDM: the need for early emphasis. Diabetes Care 1994; 17: 1469-1472.
15. Suissa S, Spitzer WO, Abenhaim L, Downey W, Gardiner RJ, Fitzgerald D. Risk of death from human insulin. Pharmacoepidemiol Drug Safe 1992; 1: 169-175.
16. Alho JM. On prevalence, incidence, and duration in general stable populations. Biometrics 1992; 48: 587-592.
17. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
18. Støvring H, Andersen M, Beck-Nielsen H, Green A, Vach W. Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 2003; 362: 537-538.
19. Kamper-Jorgensen F. The social medical Lorenz-box: inequality in society. Ugeskr Laeger 1972; 134: 345-349. (In Danish).
20. Brown M. Using Gini-style indices to evaluate the spatial patterns of health practitioners: theoretical considerations and an application based on Alberta data. Soc Sci Med 1994; 38: 1243-1256.
21. Altman DG, Bland JM. Quartiles, quintiles, centiles, and other quantiles. Br Med J 1994; 309: 996.
22. Gaist D, Sindrup SH, Hallas J, Gram LF. Misuse of sumatriptan (Letter). Lancet 1994; 344: 1090.
23. Gaist D, Tsiropoulos I, Sindrup SH, et al. Sumatriptan: a population-based study of its use based on interview and prescription register data. Br Med J 1998; 316: 1352-1353.
24. Hallas J, Nissen A. Individualised drug utilization statistics: analysing a population's drug use from a perspective of individual users. Eur J Clin Pharmacol 1994; 47: 367-372.
25. Hallas J, Gaist D, Bjerrum L. The waiting-time distribution for prescription drugs. Epidemiology 1997; 8: 666-670.
26. Schroll H, Stovring H, Houmand A, Kragstrup J. Estimating incidence and prevalence of episodes of care in general practice. Scand J Prim Health Care 2004; 22: 60-64.
27. Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering drug treatment: a comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 463-471.
28. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-461.
29. Støvring H. New statistical methods for estimation of prevalence, incidence and mortality based on pharmacoepidemiological and other health-related databases. Department of Statistics and Demography, University of Southern Denmark, 2002.
30. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986; 255: 357-360.
31. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
32. Andersen M, Gaist D, Hallas J, Maclure M. Case-crossover study of antibiotics and vaginal candidiasis: estimation of induction time and duration of effect period. Pharmacoepidemiol Drug Safe 1998; 7: S205-S206.
33. Petri H, Leufkens H, Naus J, Silkens R, Hessen PV, Urquhart J. Rapid method for estimationg the risk of acutely controversial side effect of prescription. J Clin Epidemiol 1990; 43: 433-439.
34. Hallas J. Depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996; 7: 478-485.
35. Hallas J, Bytzer P. Screening for drug-related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol 1998; 10: 27-32.